Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
AstraZeneca |
---|---|
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00640562 |
Aim of the study is to assess if the new compound Seroquel XR™ is non-inferior to Risperidone, considered as the reference drug for the treatment of depressive symptoms of schizophrenia.
PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.
Condition | Intervention | Phase |
---|---|---|
Schizophrenia Depression |
Drug: Quetiapine Extended Release Drug: Risperidone |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Parallel Assignment, Efficacy Study |
Official Title: | Comparison of Quetiapine Extended-Release (Seroquel XR™) and Risperidone Int he Treatment of Depressive Symptoms, in Schizophrenic or Schizoaffective Patients: A Randomized, Open Label, Flexible-Dose, Parallel Group, Non Inferiority, 12-Week Study |
Estimated Enrollment: | 290 |
Study Start Date: | February 2008 |
Estimated Study Completion Date: | August 2009 |
Estimated Primary Completion Date: | May 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental | Drug: Quetiapine Extended Release |
2: Active Comparator | Drug: Risperidone |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: AstraZeneca Basiglio Clinical Study Inforamtion | 02-9801-59831 |
Italy | |
Research Site | Not yet recruiting |
FRATTAMINORE, Italy | |
Research Site | Recruiting |
ROMA, Italy | |
Italy, AO | |
Research Site | Not yet recruiting |
AOSTA, AO, Italy | |
Italy, AP | |
Research Site | Recruiting |
FERMO, AP, Italy | |
Italy, BG | |
Research Site | Recruiting |
BERGAMO, BG, Italy | |
Italy, BR | |
Research Site | Recruiting |
BRINDISI, BR, Italy | |
Italy, BS | |
Research Site | Recruiting |
LENO, BS, Italy | |
Italy, CA | |
Research Site | Recruiting |
CARBONIA, CA, Italy | |
Italy, CB | |
Research Site | Recruiting |
TERMOLI, CB, Italy | |
Italy, CT | |
Research Site | Recruiting |
CATANIA, CT, Italy | |
Italy, EN | |
Research Site | Recruiting |
NICOSIA, EN, Italy | |
Italy, FG | |
Research Site | Not yet recruiting |
LUCERA, FG, Italy | |
Italy, LU | |
Research Site | Recruiting |
LIDO DI CAMAIORE, LU, Italy | |
Italy, ME | |
Research Site | Recruiting |
MESSINA, ME, Italy | |
Research Site | Recruiting |
MILAZZO, ME, Italy | |
Italy, SA | |
Research Site | Not yet recruiting |
NOCERA INFERIORE, SA, Italy | |
Research Site | Recruiting |
VALLO DELLA LUCANIA, SA, Italy | |
Italy, to | |
Research Site | Not yet recruiting |
COLLEGNO, to, Italy |
Study Director: | Gino Montagnani, MD | AstraZeneca |
Principal Investigator: | Mario diFiorino | Ospedale Unico della Versilia (Lido di Camaiore, Lucca Italy) |
Responsible Party: | AstraZeneca ( Hans Eriksson ) |
Study ID Numbers: | D1443L00031 |
Study First Received: | March 17, 2008 |
Last Updated: | December 19, 2008 |
ClinicalTrials.gov Identifier: | NCT00640562 |
Health Authority: | Italy: Ethics Committee |
Schizophrenia Depression Quetiapine |
Schizophrenia Quetiapine Dopamine Depression Mental Disorders Risperidone |
Mood Disorders Psychotic Disorders Depressive Disorder Serotonin Schizophrenia and Disorders with Psychotic Features Behavioral Symptoms |
Neurotransmitter Agents Tranquilizing Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Psychotropic Drugs Central Nervous System Depressants Dopamine Antagonists |
Antipsychotic Agents Pharmacologic Actions Serotonin Antagonists Serotonin Agents Therapeutic Uses Dopamine Agents Central Nervous System Agents |